

Remarks


Claims 1 to 7 and 17 to 26 are in the application. Claims 1 to 7, 17, 18, 20, and 21 to 26 have been made the subject of a restriction requirement.

Restriction Requirement Under 35 U.S.C. § 121 and 372

Applicants traverse the restriction. While the groups identified may be distinct, they are not independent because they arose from the same research effort and terms for one group will necessarily be shared with other groups. Therefore, doing searches on these groups combined would not be a significant burden on the Examiner. Nevertheless, in the interest of advancing the prosecution of this case, Applicants wish to make a provisional election of Group I, claims 1-7 and 17 drawn to an altered anti-MAG antibody and a pharmaceutical composition.

The Applicants reserve the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification. If it would expedite prosecution of this application, the Examiner is invited to confer with the Applicants' undersigned attorney. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Jason C. Fedon
Attorney for Applicant
Registration No. 48,138

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090